Serum amyloid A is a useful marker to evaluate the disease activity of Takayasu's arteritis

Rheumatology International

Volumn 30, Issue 4, 2010, Pages 561-563

  Koga, Tomohiro ^a   Nishino, Yuichiro ^a   Makiyama, Junya ^a   Hayashida, Takeshi ^b   Miyashita, Taichiro ^a   Izumi, Yasumori ^a   Tamai, Mami ^b   Kawakami, Atsushi ^b   Eguchi, Katsumi ^b   Migita, Kiysohi ^a  

^a NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^b NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

18F FDG PET; C reactive protein; Serum amyloid A; Takayasu's arteritis

Indexed keywords

C REACTIVE PROTEIN; CONTRAST MEDIUM; CORTICOSTEROID; FLUORODEOXYGLUCOSE F 18; METHOTREXATE; PREDNISOLONE; SERUM AMYLOID A; BIOLOGICAL MARKER; DIAGNOSTIC AGENT; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

ABDOMINAL AORTA; ADULT; AORTA ARCH SYNDROME; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ACTIVITY; DISEASE MARKER; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; INFLAMMATION; LABORATORY TEST; MEDICAL ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; THORACIC AORTA; AMYLOIDOSIS; BLOOD; DISEASE COURSE; DRUG COMBINATION; METHODOLOGY; PATHOLOGY; SCINTISCANNING; TREATMENT OUTCOME;

AMYLOIDOSIS; AORTA, THORACIC; BIOLOGICAL MARKERS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; POSITRON-EMISSION TOMOGRAPHY; PREDNISOLONE; SERUM AMYLOID A PROTEIN; TAKAYASU ARTERITIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77949877502     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-009-1296-6     Document Type: Article

References (11)

1. Weyand CM, Goronzy JJ (2003) Medium- and large-vessel vasculitis. N Engl J Med 349:160-169
2. Vanoli M, Daina E, Salvarani C, Sabbadini MG, Rossi C, Bacchiani G, Schieppati A, Baldissera E, Bertolini G, Group ItakaStudy (2005) Takayasu's arteritis: a study of 104 Italian patients. Arthritis Rheum 53:100-107
3. Ogino H, Matsuda H, Minatoya K, Sasaki H, Tanaka H, Matsumura Y, Ishibashi-Ueda H, Kobayashi J, Yagihara T, Kitamura S (2008) Overview of late outcome of medical and surgical treatment for Takayasu arteritis. Circulation 118:2738-2747
4. Borg FA, Dasgupta B (2009) Treatment and outcomes of large vessel arteritis. Best Pract Res Clin Rheumatol 23:325-337
5. Andrews J, Mason JC (2007) Takayasu's arteritis: recent advances in imaging oVer promise. Rheumatology 46:6-15
6. Salvarani C, Cantini F, Boiardi L, Hunder GG (2003) Laboratory investigations useful in giant cell arteritis and Takayasu's arteritis. Clin Exp Rheumatol 21:S23-S28
7. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, HoVman GS (1994) Takayasu arteritis. Ann Intern Med 120:919-929
8. Gabay C, Kushner I (1999) Acute phase proteins and other systemic responses to inXammation. N Engl J Med 340:448-454
9. Cunnane G, Grehan S, Geoghegan S, McCormack C, Shields D, Whitehead AS, Bresnihan B, Fitzgerald O (2000) Serum amyloid A in the assessment of early inXammatory arthritis. J Rheumatol 27:58-63 (Pubitemid 30058629)
10. Malle E, De Beer FC (1996) Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest 26:427-435
11. Park MC, Lee SW, Park YB, Lee SK (2006) Serum cytokine pro- Wles and their correlations with disease activity in Takayasu's arteritis. Rheumatology (Oxford) 45(5):545-548